Objective: To compare pre morbid FRAX score with or without Bone Mineral Density (BMD) in older patients admitted with acute hip fracture secondary to fragility, with pre admission treatment for osteoporosis. Methods: Assessing 25 acute fragility hip fractures in older patients (age >65), admitted between July 2016 to December 2016 for demographics, correlation between pre morbid fracture risk (FRAX) and prior diagnosis or treatment for osteoporosis by primary care in the community. Electronic patient record system was used to record and retrieve pre admission medications and prior diagnosis of osteoporosis. Results: 20 out of 25 patients had 10-year (FRAX) intermediate to high risk of developing hip fracture pre admission (10 intermediate, 10 high). Out of these 20, only 6 (30%) were treated for osteoporosis or osteopaenia, either by calcium/vitamin D supplement or bone protection medication, or both. 5 patients were deemed in the 'low risk' category as per FRAX score, with recommendations for lifestyle changes only, despite the fact that they were admitted with hip fracture during the time of this study. Conclusion: 1) There is a major role in the primary care setting for starting bone protection medication by only using FRAX score with or without BMD measurement as demonstrated (40% in 'high risk' category), 2) Individualised investigation and treatment for people with low to intermediate risk as guided by FRAX, taking into account clinical risk factors such as smoking and steroid use. Reference www.sheffield.ac.uk/FRAX iii13
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